

## PERSONAL INFORMATION

First name, Surname: CHIARA CROTTI

## OCCUPATIONAL FIELD

Medical Doctor (MD), Rheumatologist, PhD student

**Special interests:** spondylitis, inflammatory and psoriatic arthritides, rheumatoid arthritis, osteoporosis and osteometabolic diseases (i.e. Paget disease, fibrous dysplasia, hypophosphatasia,...), complex regional pain syndrome, Raynaud's phenomenon, connective tissue disease (systemic sclerosis, Sjögren syndrome, lupus), gout, polymyalgia, osteoarthritis, temporal arteritis, fibromyalgia.

**Research interests:** treatment of inflammatory arthritides (rheumatoid arthritis, spondyloarthritis). Bone metabolic diseases. Complex regional pain syndrome 1. Osteoporosis. Raynaud's phenomenon and capillaroscopy in connective tissue diseases.

**Publications and Clinical studies:** in attachment the list of scientific publications in journals (34) and national/international conferences (34) and participations in Clinical Studies (Trials and Observational studies) (15).

## WORK EXPERIENCE

October 2019-present

**PhD student on Clinical and Experimental Biomedical Sciences, University of Verona**

Attending at the Department of Rheumatology, ASST-Pini-CTO, piazza Cardinal Ferrari, 1, 20122 Milan (MI), Italy. Chief Prof. Roberto Caporali. New diagnosis and follow-up patients with rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, systemic sclerosis, Sjögren syndrome, systemic lupus erythematosus, other connective tissue diseases, osteoporosis, osteometabolic diseases, gout, polymyalgia rheumatic, giant cell arteritis, myositis. Research into rheumatic diseases, complex regional pain syndrome, osteometabolic diseases, systemic sclerosis, Raynaud's phenomenon, chronic inflammatory arthritides. Data entry/subinvestigator/joint assessor for Clinical trials and observational studies

August 2013  
September 2019**Residency program in Rheumatology**

- ASST Gaetano Pini- CTO, Gaetano Pini Orthopedic Institute, piazza Cardinal Ferrari, 1, 20122 Milan (MI), Italy. Rheumatology Clinic, Chief Prof. Franco Capsoni / Prof. Pierluigi Meroni. Tel (+39) 02.58296272.

July 2013  
November 2012**Medical Intern, Rheumatology,**

Department of Internal Medicine, Humanitas Research Hospital, Via Manzoni 56, Rozzano (Milano), Italy. Rheumatology Clinic, Chief Prof. Bianca Marasini.

October 2012  
June 2012

**Medical Intern, Rheumatology,**

Department of Internal Medicine, Humanitas Research Hospital, Via Manzoni 56, Rozzano (Milano), Italy. Rheumatology Clinic, Chief Prof. Bianca Marasini.

EDUCATION AND TRAINING

October 2019-Present

**PhD student on Clinical and Experimental Biomedical Sciences, University of Verona**

Attending at Day hospital Unit, Department of Rheumatology, ASST-Pini-CTO, Milan, Italy

September 2019  
August 2013

**Specialization in Rheumatology, with honors**

ASST Gaetano Pini- CTO, **Gaetano Pini Orthopedic Institute, Milan- Italy.**

July 2012

**Qualification to practice Medicine**

Università degli Studi di Milano, Milan – Italy

March 2012

**Master's degree in Medicine (MD), with honors**

Università degli Studi di Milano, Milan – Italy

PERSONAL SKILLS

Working skills and competences

Nailfold capillaroscopy, joint ultrasound (articular sonography), intra-articular (joint) injections, minor salivary gland biopsy, biopsy of subcutaneous fatty tissue.

Mother tongue(s)

Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	C1	B2	B2	C1
French	B1	B2	B2	B1	B1

Levels: A1/A2: Basic user - B1/B2: Independent user - C1/C2 Proficient user

European language levels: <http://europass.cedefop.europa.eu/resources/european-language-levels-cefr>

Communication, organisational and other skills and competences

Experienced at giving presentations to audiences (poster presentation and oral communications at conferences or congresses, speaker at scientific meetings). Excellent organisational and prioritisation skills.

Member of Società Italiana di Reumatologia (SIR), of Società Italiana dell'Osteoporosi del Metabolismo Minerale e delle Malattie dello Scheletro (SIOMMMS), of Web and social media commission of SIOMMMS, and of YES Group SIOMMMS. Member of EMEUNET.

Computer skills and competences

▪ Proficient with Microsoft Office (Word, Powerpoint, Excel), excellent knowledge of e-mail services (Outlook) and Internet Explorer/Google Chrome/Firefox. Basic user of statistical software STATA.

Date 16.11.2021


**List of publications in scientific journals**
**Author/Co-author**

1. Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study. Varenna M, Braga V, Gatti D, Iolascon G, Frediani B, Zucchi F, **Crotti C**, Nannipieri F, Rossini M. *Ther Adv Musculoskelet Dis*. 2021 Jun 11;13:1759720X211014020. doi: 10.1177/1759720X211014020.
2. A novel mutation in collagen gene COL1A2 associated with transient regional osteoporosis. Varenna M, **Crotti C**, Bonati MT, Zucchi F, Gallazzi M, Caporali R. *Osteoporos Int*. 2021 Aug 31. doi: 10.1007/s00198-021-06135-7.
3. Tumor induced osteomalacia: A single center experience on 17 patients. **Crotti C**, Bartoli F, Coletto LA, Manara M, Marini E, Daolio PA, Parafioriti A, Armiraglio E, Zucchi F, Sinigaglia L, Caporali R, Varenna M. *Bone*. 2021 Nov;152:116077. doi: 10.1016/j.bone.2021.116077.
4. Decreasing severity of Paget's disease of bone in northern Italy over the last two decades: results of a monocentric study on 391 patients. Varenna, M., Zucchi, F., **Crotti, C.**, Manara, M., Caporali, R. *Osteoporosis international*. 2021. DOI: 10.1007/s00198-020-05789-z.
5. Publishing in 2@84. Lanzillotta M, **Crotti C**, Da Silva Domingues VM, Lauper K, Burmester GR. *Ann Rheum Dis*. 2021;80:11-13.
6. Determinants of Diagnostic Delay in Complex Regional Pain Syndrome Type 1: An Observational Study of 180 Consecutive New Cases. Varenna M, **Crotti C**, Ughi N, Zucchi F, Caporali R. *J Clin Rheumatol*. 2020. doi: 10.1097/RHU.0000000000001558.
7. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Biggioggero M, Becciolini A, **Crotti C**, Agape E, Favalli EG. *Drugs Context*. 2019;8:212595. doi: 10.7573/dic.212595.
8. Effectiveness and tolerability of repeated courses of viscosupplementation in symptomatic hip osteoarthritis: a retrospective observational cohort study of high molecular weight vs. medium molecular weight hyaluronic acid vs. no viscosupplementation. De Lucia O, Pierannunzi LM, Pregnotato F, Verduci E, **Crotti C**, Valcamonica E, Pisoni L, Comi D, Lonati PA, Meroni PL, Murgo A. *Front Pharmacol* 2019;10:1007. Doi:10.3389/fphar.201901007
9. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. **Crotti C**, Agape E, Becciolini A, Biggioggero M, Favalli EG. *Drugs*. 2019 Sep 4. doi: 10.1007/s40265-019-01192-z
10. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. **Crotti C**, Biggioggero M, Becciolini A, Agape E, Favalli EG. *Expert Opin Investig Drugs*. 2019;28:573-581.
11. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Biggioggero M, **Crotti C**, Becciolini A, Favalli EG. *Drug Des Devel Ther*. 2018;13:57-70.
12. The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. Biggioggero M, **Crotti C**, Becciolini A, Miserocchi E, Favalli EG. *Biomed Res Int*. 2018 Oct 14;2018:9460187. doi: 10.1155/2018/9460187.
13. Sarilumab: patient-reported outcomes in rheumatoid arthritis. **Crotti C**, Biggioggero M, Becciolini A, Favalli EG. *Patient Relat Outcome Meas*. 2018;9:275-284.
14. Bisphosphonates in the treatment of complex regional pain syndrome: is bone the main player at early stage of the disease? Varenna M, **Crotti C**. *Rheumatol Int*. 2018; doi: 10.1007/s00296-018-4101-6.
15. The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. Favalli EG, Becciolini A, Biggioggero M, Bertoldi I, **Crotti C**, Raimondo MG, Marchesoni A. *Drug Des Devel Ther*. 2018;12:1421-1429.
16. Acute phase reactions after zoledronic acid infusion: protective role of 25-OH vitamin D and previous oral bisphosphonate therapy. **Crotti C**, Watts NB, De Santis M, Ceribelli A, Fabbriani G, Cavaciocchi F, Marasini B, Selmi C, Massarotti M. *Endocr Pract*. 2018. doi: 10.4158/EP161638. PMID: 29498910.
17. Sex and Management of Rheumatoid Arthritis. Favalli EG, Biggioggero M, **Crotti C**, Becciolini A, Raimondo MG, Meroni PL. *Clin Rev Allergy Immunol*. 2019;56:333-345. PMID: 29372537.
18. The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. Favalli EG, Raimondo MG, Becciolini A, **Crotti C**, Biggioggero M, Caporali R. *Autoimmun Rev*. 2017;16:1185-1195. PMID: 29037899.
19. Vitamin D and spondyloarthritis: Review of the literature. **Crotti, C.**, Becciolini, A., Biggioggero, M., Favalli, E.G. *Open Rheumatology Journal*, 2018:214–225
20. Outcomes, rates and predictors of transition of isolated Raynaud's phenomenon: a systematic review and meta-analysis. Ingegnoli F, Ughi N, **Crotti C**, Mosca M, Tani C. *Swiss Med Wkly*. 2017;147:w14506. PMID: 28975961.
21. A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. Becciolini A, Raimondo MG, **Crotti C**, Agape E, Biggioggero M, Favalli EG. *Drug Des Devel Ther*. 2017;11:1969-1978. PMID: 28721016.
22. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, **Crotti C**, Gattinara M, Gerloni V, Marchesoni A, Meroni PL. *Clin Rheumatol*. 2017;36:1747-1755. PMID: 28597133.
23. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Raimondo MG, Biggioggero M, **Crotti C**, Becciolini A, Favalli EG. *Drug Des Devel Ther*. 2017;11:1593-1603. PMID: 28579757.
24. Nailfold scleroderma-like capillary abnormalities in Werner syndrome (adult progeria). Ingegnoli F, **Crotti C**. *Vasc Med*.

- 2017;22:246-247. PMID: 28466674.
25. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. **Crotti C**, Raimondo MG, Becciolini A, Biggioggero M, Favalli EG. *Drug Des Devel Ther*. 2017;11:211-223. PMID: 28144129.
  26. The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting. Di Carlo M, Becciolini A, Lato V, **Crotti C**, Favalli EG, Salaffi F. *J Rheumatol*. 2017;44:279-285. PMID: 27909086.
  27. Effects of type II collagen epitope carbamylation and citrullination in human leucocyte antigen (HLA)-DR4(+) monozygotic twins discordant for rheumatoid arthritis. De Santis M, Ceribelli A, Cavaciocchi F, Generali E, Massarotti M, Isailovic N, **Crotti C**, Scherer HU, Montecucco C, Selmi C. *Clin Exp Immunol*. 2016;185:309-19. PMID: 27314557.
  28. Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports. Ughi N, **Crotti C**, Ingegnoli F. *Clin Interv Aging*. 2016;11:307-11. PMID: 27042030.
  29. Nailfold videocapillaroscopy and serum VEGF levels in scleroderma are associated with internal organ involvement. De Santis M, Ceribelli A, Cavaciocchi F, **Crotti C**, Massarotti M, Belloli L, Marasini B, Isailovic N, Generali E, Selmi C. *Auto Immun Highlights*. 2016;7:5. PMID: 26878864.
  30. Mesenchymal stem cells: potential for therapy and treatment of chronic non-healing skin wounds. Marfia G, Navone SE, Di Vito C, Ughi N, Tabano S, Miozzo M, Tremolada C, Bolla G, **Crotti C**, Ingegnoli F, Rampini P, Riboni L, Gualtierotti R, Campanella R. *Organogenesis*. 2015;11:183-206. PMID: 26652928.
  31. Gamma-delta T lymphocytes and 25-hydroxy vitamin D levels as key factors in autoimmunity and inflammation: the case of zoledronic acid-induced acute phase reaction. De Santis M, Cavaciocchi F, Ceribelli A, **Crotti C**, Generali E, Fabbriani G, Selmi C, Massarotti M. *Lupus*. 2015;24:442-7. PMID: 25801887.
  32. Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis. Selmi C, Cavaciocchi F, Lleo A, Cheroni C, De Francesco R, Lombardi SA, De Santis M, Meda F, Raimondo MG, **Crotti C**, Folci M, Zammataro L, Mayo MJ, Bach N, Shimoda S, Gordon SC, Miozzo M, Invernizzi P, Podda M, Scavelli R, Martin MR, Seldin MF, Lasalle JM, Gershwin ME. *Front Immunol*. 2014;5:128. PMID: 24734033.
  33. Liver abnormalities in connective tissue diseases. De Santis M, **Crotti C**, Selmi C. *Best Pract Res Clin Gastroenterol*. 2013;27:543-51. PMID: 24090941.
  34. Less travelled roads in clinical immunology and allergy: drug reactions and the environmental influence. Selmi C, **Crotti C**, Meroni PL. *Clin Rev Allergy Immunol*. 2013;45:1-5. PMID: 23842719.

#### List of publications in scientific national/international conferences

##### EUROPEAN CONGRESS OF RHEUMATOLOGY (EULAR)

35. Tumor-induced osteomalacia: data from a monocentric experience on 16 patients. **C. Crotti**, F. Bartoli, M. Manara, P. A. Daolio, F. Zucchi, R. Caporali, L. Sinigaglia, M. Varenna. *Ann Rheum Dis*, 2020;79 (Suppl 1): pg 444.
36. Burosumab (anti-FGF23 monoclonal antibody) in the treatment of a patient with recurrent tumor induced osteomalacia. **C. Crotti**, F. Zucchi, P. Messa, R. Caporali, M. Varenna. *Ann Rheum Dis*, 2020;79 (Suppl 1): pg 1758.
37. Clinical presentation of Paget disease of bone: is it changing? A retrospective analysis on 368 patients. **C. Crotti**, F. Zucchi, A. Becciolini, L. Sinigaglia, M. Varenna. *Ann Rheum Dis* 2019; 78 (Suppl 2): A1296.
38. Nerve growth factor, sclerostin and DKK-1 serum levels in complex regional pain syndrome1 (CRPS-1): a pilot study on 41 patients. **C. Crotti**, M. Manara, F. Zucchi, D. Gatti, M. Rossini, M. Varenna. *Ann Rheum Dis* 2019; 78 (Suppl 2): A568.
39. Comorbidities affect the retention rate but not the clinical response in a cohort of rheumatoid arthritis patients treated with tumor necrosis factor inhibitors. E. G. Favalli, M. Biggioggero, A. Becciolini, **C. Crotti**, L. Sinigaglia. *Ann Rheum Dis* 2018; 77 (Suppl): A928.
40. Sonographic persistence of subclinical joint and tendon inflammation in rheumatoid arthritis patients achieving sustained clinical remission on synthetic or biologic drug therapy: preliminary data of a cross-sectional study. A. Becciolini, E.G. Favalli, M. Di Carlo, M. Biggioggero, **C. Crotti**, F. Salaffi, P.L. Meroni. *Ann Rheum Dis* 2016; 75(Suppl 2):959.
41. Outcomes, rates, and risk factors of transition of raynaud's phenomenon to a connective tissue disease: systematic review and meta-analysis. N. Ughi, F. Ingegnoli, **C. Crotti**, M. Mosca, C. Tani. *Ann Rheum Dis* 2016; 75(Suppl 2):886.
42. Role of methotrexate as combination therapy with adalimumab and etanercept in rheumatoid arthritis: retrospective analysis from a local registry. E.G. Favalli, A. Becciolini, M. Biggioggero, **C. Crotti**, N. Ughi, A.E. Penatti, A. Marchesoni, P.L. Meroni. *Ann Rheum Dis* 2016; 75(Suppl 2):49.
43. Six-year retention rate of abatacept in rheumatoid arthritis: a multicentric retrospective analysis. E.G. Favalli, C. Botsios, C. Bazzani, B. Raffainer, G. Ciancio, A. Giollo, A. Marchesoni, R. Gorla, C. Caimmi, A. Becciolini, **C. Crotti**, S. Piantoni, M. Biggioggero, A. Carletto. *Ann Rheum Dis* 2016; 75(Suppl 2):509.
44. Prevalence and predictive value of serum autoantibodies in the general population: results of a longitudinal study on 2690 subjects with a 13-year observation. C. Selmi, F. Alborghetti, S. Pfeiffer, G. Colloredo, M. I. Achenza, F. Cavaciocchi, V. Paleari, M. S. Massarotti, E. Brunetta, G. Fabbriani, M. De Santis, F. Meda, A. Ceribelli, **C. Crotti**, L. Porrati, P. Invernizzi, M. Podda, T. Matthias, P. L. Meroni. *Ann Rheum Dis* 2013; 72(Suppl s3).
45. Comparison of two different intra-articular hyaluronidic acid compounds for carpo-metacarpal joint osteoarthritis. M. Massarotti, **C. Crotti**, N. Ughi, F. Uboldi, L. Belloli, B. Marasini. *Ann Rheum Dis* 2012; 71(Suppl 3):695.
46. Heterogeneity of patients with anticentromere antibodies. L. Belloli, **C. Crotti**, N. Ughi, M. Massarotti, B. Marasini. *Ann Rheum Dis* 2012; 71(Suppl 3):715.
47. Extracorporeal shock wave therapy for skin involvement in systemic sclerosis: preliminary data. N. Ughi, L. Belloli, M.C. D'Agostino, **C. Crotti**, M. Massarotti, S. Respizzi, B. Marasini. *Ann Rheum Dis* 2011; 70(Suppl 3):730.

48. Acute-phase response after zoledronic acid: role of vitamin d and of previous treatment with oral amino-bisphosphonates. M. Massarotti, **C. Crotti**, N. Ughi, G. Fabbriani, L. Belloli, B. Marasini. *Ann Rheum Dis* 2011; 70(Suppl 3):234.
49. Teriparatide for prevention of subsequent vertebral fractures after vertebroplasty. M. Massarotti, F. Tancioni, **C. Crotti**, N. Ughi, G. Fabbriani, L. Belloli, B. Marasini. *Ann Rheum Dis* 2011; 70(Suppl 3):235.

AMERICAN COLLEGE FOR RHEUMATOLOGY ANNUAL MEETING (ACR/ARHP)

50. Acute-phase response after zoledronic acid: role of vitamin D and of previous treatment with oral amino-bisphosphonates. M. Massarotti, **C. Crotti**, N. Ughi, G. Fabbriani, L. Belloli, B. Marasini. *Arthritis & Rheumatism* 2011;63(10):S691.

ITALIAN SOCIETY FOR RHEUMATOLOGY ANNUAL MEETING (SIR)

51. Valutazione a lungo termine della sindrome algodistrofica dopo trattamento con Neridronato EV. Studio monocentrico longitudinale su una coorte di 71 pazienti. G. Calabrese, **C. Crotti**, F. Zucchi, R. Caporali, M. Varenna. *Reumatismo* 2020;72:414.
52. Il ruolo di Nerve Growth Factor, sclerostina e DKK-1 nella patogenesi della complex regional pain syndrome 1 (CRPS-1): risultati di uno studio pilota su 41 pazienti. **C. Crotti**, M. Manara, F. Zucchi, D. Gatti, M. Rossini, M. Varenna. *Reumatismo* 2019;71:110.  
ORAL COMUNICATION
53. Osteomalacia oncogenica: analisi retrospettiva monocentrica su 15 pazienti. F. Bartoli, **C. Crotti**, M. Manara, L.A. Coletto, P. Daolio, F. Zucchi, M. Varenna, L. Sinigaglia. *Reumatismo* 2019;71:172. ORAL COMUNICATION
54. La malattia di Paget sta cambiando? Analisi retrospettiva su un campione di 368 pazienti. **C. Crotti**, N. Ughi, A. Becciolini, F. Zucchi, L. Sinigaglia, M. Varenna. *Reumatismo* 2018;70 (suppl2): 236. ORAL COMMUNICATION
55. Confronto tra i criteri di inclusione dei trial regolativi e la pratica clinica in pazienti affetti da artrite psoriasica candidabili ad una terapia biologica: differenze di selezione della popolazione e persistenza in terapia a 10 anni. **C. Crotti**, M. Biggioggero, A. Becciolini, E. Agape, E.G. Favalli. *Reumatismo* 2018;70 (suppl2): 360.
56. La popolazione di pazienti affetti da Artrite Reumatoide trattati con farmaci biologici nella pratica clinica è sensibilmente diversa da quella selezionata dai criteri di inclusione dei trial clinici randomizzati controllati e presenta una maggior retention rate a 10 anni: analisi retrospettiva di un ampio registro locale. A. Becciolini, E. Agape, **C. Crotti**, M. Biggioggero, E.G. Favalli. *Reumatismo* 2018;70 (suppl2): 411.
57. Caratteristiche basali e razionale nella prescrizione di Apremilast in un'ampia casistica multicentrica italiana di pazienti affetti da Artropatia psoriasica. **C. Crotti**, C. Zuccaro, C. Selmi, R. Bucci, F. D'Onofrio, G. Carlino, L. Santo, A. Semeraro, S. Monti, D. Mazzotta, F. Atzeni, R. Caporali, F. Iannone, E.G. Favalli. *Reumatismo* 2018;70 (suppl2): 359.
58. L'impatto delle comorbidità sulla scelta della terapia biologica e sulla risposta clinica: analisi retrospettiva di una coorte di pazienti affetti da Artrite Reumatoide trattati con una prima linea biologica con farmaci anti-tumor necrosis factor. M. Biggioggero, A. Becciolini, **C. Crotti**, E. Agape, E.G. Favalli. *Reumatismo* 2018;70 (suppl2):410.

59. Le manifestazioni extra-articolari in corso di spondiloartrite assiale influenzano la scelta del farmaco biologico? Dati da una casistica multicentrica real life. **C. Crotti**, E.G. Favalli, S. D'Angelo, A. Carletto, A. Becciolini, F. Martinis, G. Tramontano, M. Biggioggero, A. Marchesoni, M. Rossini. *Reumatismo* 2017;69 (suppl2):56. ORAL COMMUNICATION
60. Fattori predittivi di persistenza in trattamento a lungo termine di abatacept: analisi retrospettiva di una casistica multicentrica di pazienti affetti da artrite reumatoide. **C. Crotti**, E.G. Favalli, A. Carletto, R. Gorla, R. Foti, A. Becciolini, F. Martinis, C. Bazzani, A. Giollo, S. Piantoni, L. Sinigaglia. *Reumatismo* 2017;69 (suppl2):184. ORAL COMMUNICATION
61. Methotrexate come terapia di combinazione con una prima linea di terapia biologica con adalimumab o etanercept nell'artrite reumatoide: ruolo della posologia basale e del suo mantenimento nel tempo. M. Biggioggero, A. Becciolini, **C. Crotti**, M.G. Raimondo, I. Bertoldi, E.G. Favalli. *Reumatismo* 2017;69 (suppl2):186. ORAL COMMUNICATION
62. I determinanti del ritardo diagnostico in corso di sindrome algodistrofica (CRPS-I): risultati di uno studio prospettico su 124 pazienti. **C. Crotti**, N. Ughi, A. Becciolini, F. Zucchi, L. Sinigaglia, M. Varenna. *Reumatismo* 2017;69 (suppl2):199. ORAL COMMUNICATION
63. La scelta del farmaco biologico di prima linea per il trattamento dell'artrite reumatoide: confronto di efficacia e persistenza in terapia tra blocco del tnf e dell'IL-6 in una casistica retrospettiva. E.G. Favalli, A. Becciolini, **C. Crotti**, M. Biggioggero, E. Agape, A. Marchesoni, P.L. Meroni. *Reumatismo* 2016;68(Suppl3):204.
64. Le manifestazioni extra-articolari in corso di spondiloartrite assiale in trattamento con farmaci biotecnologici: quale prevalenza e quale ruolo nella scelta del singolo inibitore del tnf? analisi retrospettiva di un registro locale. E.G. Favalli, A. Becciolini, M. Biggioggero, **C. Crotti**, E. Agape, A. Marchesoni, P.L. Meroni. *Reumatismo* 2016;68(Suppl3):332.
65. L'introduzione del biosimilare di etanercept nella pratica di un centro reumatologico di terzo livello: un modello di budget impact. A. Becciolini, E. Psachoulia, M. Biggioggero, **C. Crotti**, E. Agape, C. Negrini, E.G. Favalli. *Reumatismo* 2016;68(Suppl3):395.
66. Indicatori, fattori di rischio e predittori di transizione da fenomeno di Raynaud a malattia del connettivo: dati da una review sistematica e meta-analisi. **C. Crotti**, N. Ughi, M. Mosca, C. Tani, F. Ingegnoli. *Reumatismo* 2016;68(Suppl3):439.
67. Ruolo del methotrexate come terapia di associazione in corso di trattamento con adalimumab ed etanercept nell'artrite reumatoide: analisi retrospettiva di un registro locale. A. Becciolini, E.G. Favalli, **C. Crotti**, N. Ughi, A.E. Penatti, M. Biggioggero, A. Marchesoni, P.L. Meroni. *Reumatismo* 2015;67(suppl3):238.
68. Persistenza in terapia e motivi di sospensione del trattamento con farmaci anti-tumor necrosis factor alpha in una coorte di pazienti affetti da artropatia ad esordio in età giovanile e adulta. M. Biggioggero, E.G. Favalli, I. Pontikaki, N. Ughi, A. Becciolini, A. E. Penatti, **C. Crotti**, A. Marchesoni, V. Gerloni, P.L. Meroni. *Reumatismo* 2015;67(suppl3):239.
69. Il tipo di amino-bisfosfonato orale e i livelli di vitamina D influenzano la reazione di fase acuta da zoledronato? M. Massarotti, **C. Crotti**, G. Fabbriani, L. Belloli, N. Ughi, B. Marasini. *Reumatismo* 2011;63(suppl3):212.

#### European Congress on Osteoporosis & Osteoarthritis (ECCEO11-IOF)

70. Massarotti M., Tancioni F., Crotti C., Fabbriani G., Belloli L., Ughi N., Marasini B. May teriparatide prevent subsequent vertebral fractures after vertebroplasty? *Osteoporosis International* 2011; 22 SUPPL 1 (S255).

#### Book chapter

71. Glutamic acid decarboxylase autoantibodies. **Crotti C**, Selmi C Autoantibodies edited by: Y. Shoenfeld, M. E. Gershwin, P.L. Meroni, III edition 2013- Ed. Elsevier
72. Antiphospholipid Antibody Mechanisms of Thrombosis. Meroni PL, **Crotti C**, Chighizola C. In *Antiphospholipid Antibody Syndrome: From Bench to Bedside* 2015 (pp. 25-35) -Ed. Springer International Publishing Switzerland.

#### Participation in Clinical Studies (Trial and observational studies)

73. **Data Manager/sub-investigator** of observational and randomized clinical trials: **DUO registry** (Digitals Ulcers Associated with Systemic Sclerosis); **DU Registry** (Digitals Ulcers in Systemic Sclerosis); clinical study **KING** (Kick-off of the Italian Network for Gout); **ALX-HPP-501 registry**; clinical Study **NAIMES/32**; Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (**TRUST**); clinical study **MARI** (Metotressato nella terapia dell'Artrite Reumatoide), clinical study **TOHNER/31**.
74. **Joint assessor** of randomized clinical trials: **1F-MC-RHBE** and **IM 101-550**.